Quality of life with Nuplazid was significantly improved for PDP pts. i.e. T of Hallucinations, delusions and MDD in about a third of the pts suffering from MDD.
Surely ADP patients would benefit from an improved quality of life in their last years or months. ???
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID(R) (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis Scheduled for June 17, 2022 2022-05-02 04:05:07 PM ET (BusinessWire)